The inhibition mediated by the CS1/CRT fusion DNA vaccine on the tumor cells was greater than that of the pcDNA3.1-CS1 plasmid, suggesting that the use of CRT as an immune adjuvant may enhance the inhibitory effect of the CS1-DNA vaccine on myeloma cells. The gene discussed is CALR; the disease is plasma cell myeloma.